Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lupin Limited ( (IN:LUPIN) ) has issued an announcement.
Lupin Limited’s subsidiary, Lupin Healthcare (UK) Limited, has acquired the entire share capital of Renascience Pharma Limited, a UK-based pharmaceutical company. This acquisition is set to expand Lupin’s portfolio of specialty pharmaceuticals in the UK, enhancing its market positioning and offering potential growth opportunities in the region.
More about Lupin Limited
Lupin Limited operates in the pharmaceutical industry, focusing on the development, production, and marketing of a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The company has a strong market presence in various global markets, including the United Kingdom.
YTD Price Performance: -17.28%
Average Trading Volume: 16,057
Current Market Cap: 925.2B INR
Find detailed analytics on LUPIN stock on TipRanks’ Stock Analysis page.